To Consider:

Look deep into nature, and then you will understand everything better.

Albert Einstein (1879-1955) German-born theoretical physicist

Terrazas del Rodeo

EMA recommends Nuvaxovid for authorisation in the EU

More
9 months 2 weeks ago - 9 months 2 weeks ago #1 by Editor
The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Novavax’s COVID-19 vaccine Nuvaxovid (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age.

How Nuvaxovid works
Nuvaxovid works by preparing the body to defend itself against COVID-19. The vaccine contains a version of a protein found on the surface of SARS-CoV-2 (the spike protein), which has been produced in the laboratory. It also contains an ‘adjuvant’, a substance to help strengthen the immune responses to the vaccine.

When a person is given the vaccine, their immune system will identify the protein as foreign and produce natural defences — antibodies and T cells — against it. If, later on, the vaccinated person comes into contact with SARS-CoV-2, the immune system will recognise the spike protein on the virus and be prepared to attack it. The antibodies and immune cells can protect against COVID-19 by working together to kill the virus, prevent its entry into the body’s cells and destroy infected cells.

Nuvaxovid is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.

www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu

Please Log in or Create an account to join the conversation.

Moderators: Administrator
Powered by Kunena Forum